The recent approval of trastuzumab deruxtecan (T-DXd), a novel ADC targeting human epidermal growth factor receptor 2 (HER2) (Figure 1), for various lines of therapy and indications in breast cancer has highlighted this issue and is the focus of this review. This evidence concerns the gene ERBB2 and breast carcinoma.